Drug – bio-affecting and body treating compositions – Inorganic active ingredient containing – Heavy metal or compound thereof
Patent
1989-08-31
1993-04-13
Rizzo, Nicholas S.
Drug, bio-affecting and body treating compositions
Inorganic active ingredient containing
Heavy metal or compound thereof
514211, 514356, 514492, 514523, 514861, 514887, A61K 3324, A61K 3128
Patent
active
052021300
ABSTRACT:
Treatment of an animal with calcium flux inhibitors results in a decrease in the number of epidermal Langerhans cells and a simultaneous decrease in the ability to respond to contact sensitizing agents. Also, topical application of calcium flux inhibitors will reduce inflammation in patients experiencing delayed-type hypersensitivity reaction or atopic eczema. Thus, calcium flux inhibitors represent a new class of therapeutic agents in the treatment of contact dermatitis and eczema.
REFERENCES:
patent: 4485054 (1984-11-01), Mezei et al.
patent: 4556560 (1985-12-01), Buckingham
"Suppression of Cutaneous Hypersensitivity" by Lanthanum in clinical research, 37(2) 1989, p. 349A; National meeting of the American Federation for Clinical Research Washington D.C., U.S.A.
"CRC Handbook of Chemistry and Physics" 66th edition 1985-86 p. F-164 Editor--in--Chief R. C. Weast.
Evans, C. H., "Interestin and useful biochemical properties of lanthanides", Trends in Biochemical Sciences, 1983, vol. 8, pp. 445-449.
Epstein (1987), in Fitzpatrick, et al., eds., Dermatology in General Medicine, McGraw-Hill, New York, pp. 1373-1383.
Texbook of Dermatology, 4th ed., Rook, et al., eds., Blackwell Scientific Publications, Oxford, 1986, pp. 239-244.
Toews, et al. "Epidermal Langerhans Cell Density Determines Whether Contact Hypesensitivity or Unresponsiveness Follows Skin Painting with DNFB," J. Immunol. (1980), 124:445-453.
Noonan, et al. "Suppression of Contact Hypersensitivity in Mice by Ultraviolet Irradiation is Associated with Defective Antigen Presentation," Immunol. (1981), 43:527-533.
Perry et al., "Antigen Presentation by Epidermal Langerhans Cells: Loss of Function Following Ultraviolet (UV) Irradiation in vivo," Clin. Immunol. Immunopath. (1982), 24:204-219.
Belsito et al, "Effect of Glucocorticosteriods on Epidermal Langerhans Cells," J. Exp. Med. (1982), 155:291-302.
Krueger et al., "Biology of Langerhans Cells: Analysis by Experiments to Deplete Langerhans Cells from Human Skin," J. Invest. Dermatol. (1984), 82:613-617.
Rheins et al., "Modulation of the Population Density of Identifiable Epidermal Langerhans Cells Associated with Enhancement or Suppression of Cutaneous Immune Reactivity," J. Immunol. (1986), 136:867-876.
Miyauchi et al., "Epidermal Langerhans Cells Undergo Mitosis During the Early Recovery Phase After Ultraviolet-B Irradiation," J. Invest. Dermatol. (1987), 88:703-708.
Wolff et al., "An Electron Microscopic Study on the Extraneous Coat of Keratinocytes and the Intercellular Space of the Epidermis," J. Invest. Dermatol. (1968), 51:418-430.
Basu et al., "Neurotoxicity of Lanthanum Chloride in Newborn Chicks," Toxicol. Letters (1982), 14:21-25.
Schneider et al., "Secretion of Granule Enzymes from Alveolar Macrophages," Experiment. Cell Res. (1978), 112:249-256.
Onozaki et al., "The Mechanism of Macrophage Activation Induced by Ca.sup.2+ Ionophore," Cell. Immunol. (1983), 75:242-254.
Morse et al., "Effect of Nifedipine of 67K Calcimedin in Cultured Macrophages and Smooth Muscle Cells," Biochem. Biophys. Res. Comm. (1987), 145:726-732.
Lee et al, "Mechanism of Calcium Channel Blockade by Verapamil, D600, Diltiazem and Nitrendipine in Single Dialysed Heart Cells," Nature (1983), 302:790-794.
Mezei, "Liposomes in the Topical Application of Drugs: a Review," in "Liposomes as Drug Carriers," ed. Gregoriadis, Wiley and Sons, pp. 663-667.
Diezel, "Suppression of Cutaneous Contact Hypersensitivity by Calcium Transport Inhibitors Lanthanum and Diltiazem," Abstract, Clin. Res. (1988), 36:813A.
Diezel, "Suppression of Cutaneous Contact Hypersensitivity by Lanthanum," Abstract, Clin. Res. (1989)m 37:349A.
Diezel, "Inhibition of Cutaneous Contact Hypersensitivity by Calcium Transport Inhibitors Lanthanum and Diltiazem," J. Invest. Dermatol. (1989),
The U.S. Government has a paid-up license in this invention and the right in limited circumstances to require the patent owner to license others on reasonable terms as provided for by the terms of Grants number R1AR32490 and KO4AR016868 awarded by the National Institutes of Health.
Grant Anhalt
Wolfgang Diezel
Rizzo Nicholas S.
The Johns Hopkins University
Venkat Jyothsna
LandOfFree
Suppression of eczematous dermatitis by calcium transport inhibi does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Suppression of eczematous dermatitis by calcium transport inhibi, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Suppression of eczematous dermatitis by calcium transport inhibi will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1153964